Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.
暂无分享,去创建一个
A. Schneider | G. Dubin | T. Schwarz | D. Descamps | J. Wysocki | S. Poncelet | T. Zahaf | M. Spaczyński | K. Hardt | P. Perona | A. Gałaj